| scholarly article | Q13442814 |
| P50 | author | Anna Valeria Vergoni | Q59198170 |
| Barbara Ruozi | Q39549923 | ||
| Giovanni Tosi | Q39549958 | ||
| Flavio Forni | Q39550000 | ||
| Maria Angela Vandelli | Q39550040 | ||
| Anna Ferrari | Q39803399 | ||
| P2093 | author name string | Francesco Rivasi | |
| Luca Badiali | |||
| Lucia Bondioli | |||
| P2860 | cites work | Ubiquitylation of leptin receptor OB-Ra regulates its clathrin-mediated endocytosis | Q24304963 |
| The use of lead citrate at high pH as an electron-opaque stain in electron microscopy | Q26778439 | ||
| Gene expression in arcuate nucleus-median eminence of rats treated with leptin or ciliary neurotrophic factor | Q28565849 | ||
| Structure and function of the blood-brain barrier | Q29615699 | ||
| Identification and expression cloning of a leptin receptor, OB-R | Q29620255 | ||
| Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery | Q33955046 | ||
| Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins | Q34035426 | ||
| TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs | Q34818171 | ||
| Short communication: Tissue distribution of leptin and leptin receptor mRNA in the bovine | Q35195023 | ||
| Influence of surface-modifying surfactants on the pharmacokinetic behavior of 14C-poly (methylmethacrylate) nanoparticles in experimental tumor models. | Q52960129 | ||
| Brain drug delivery of small molecules using immunoliposomes | Q35947016 | ||
| Polymeric nanoparticles for the drug delivery to the central nervous system | Q37076360 | ||
| Developing drugs that can cross the blood-brain barrier: applications to Alzheimer's disease | Q37353187 | ||
| Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases | Q37576225 | ||
| In vivo methods to study uptake of nanoparticles into the brain. | Q37798178 | ||
| Epitope mapping of secreted mouse leptin utilizing peripherally administered synthetic peptides | Q38316016 | ||
| Modulation of nucleic acid structure by ligand binding: induction of a DNA.RNA.DNA hybrid triplex by DAPI intercalation. | Q38345373 | ||
| Near complete rescue of experimental Parkinson's disease with intravenous, non-viral GDNF gene therapy | Q39902228 | ||
| Development of a pharmacologically improved peptide agonist of the leptin receptor | Q39972101 | ||
| Convergent trafficking pattern of leptin after endocytosis mediated by ObRa-ObRd | Q40166509 | ||
| Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution. | Q43118634 | ||
| Leptin-derived peptide, a targeting ligand for mouse brain-derived endothelial cells via macropinocytosis. | Q43137017 | ||
| A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. | Q43248430 | ||
| Surface modification of poly(lactic acid) nanoparticles by covalent attachment of thiol groups by means of three methods | Q44277706 | ||
| Brain uptake of thiamine-coated nanoparticles | Q44673525 | ||
| Poly(lactic acid) nanoparticles labeled with biologically active Neutravidin for active targeting | Q45080918 | ||
| Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution | Q46063843 | ||
| Leptin inhibits hypothalamic Npy and Agrp gene expression via a mechanism that requires phosphatidylinositol 3-OH-kinase signaling. | Q46620831 | ||
| Targeting of daunomycin using biotinylated immunoliposomes: pharmacokinetics, tissue distribution and in vitro pharmacological effects | Q46731833 | ||
| Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier | Q46758385 | ||
| Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method | Q47758963 | ||
| Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. | Q48096517 | ||
| Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer | Q48120696 | ||
| A leptin derived 30-amino-acid peptide modified pegylated poly-L-lysine dendrigraft for brain targeted gene delivery | Q48240744 | ||
| Global non-viral gene transfer to the primate brain following intravenous administration | Q48393623 | ||
| Regional localization of specific [125I]leptin binding sites in rat forebrain | Q48462371 | ||
| Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats | Q48587255 | ||
| Neuromedin U partially mediates leptin-induced hypothalamo-pituitary adrenal (HPA) stimulation and has a physiological role in the regulation of the HPA axis in the rat. | Q48606965 | ||
| Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones | Q48706032 | ||
| The identification of leptin-derived peptides that are taken up by the brain | Q48734007 | ||
| Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier | Q48774664 | ||
| Effects of peripheral 5-HT2 and 5-HT3 receptor agonists on food intake in food-deprived and 2-deoxy-D-glucose-treated rats | Q48778910 | ||
| Mapping of the interface between leptin and the leptin receptor CRH2 domain | Q49114793 | ||
| Leptin access into the brain: a saturated transport mechanism in obesity | Q50118046 | ||
| P433 | issue | 3 | |
| P921 | main subject | nanoparticle | Q61231 |
| P304 | page(s) | 365-382 | |
| P577 | publication date | 2011-09-30 | |
| P1433 | published in | Nanomedicine | Q15817508 |
| P1476 | title | Can leptin-derived sequence-modified nanoparticles be suitable tools for brain delivery? | |
| P478 | volume | 7 |
| Q39164804 | Blood-brain barrier transport machineries and targeted therapy of brain diseases. |
| Q49102381 | Brain targeting with polymeric nanoparticles: which administration route should we take? |
| Q39438422 | Brain-targeted polymeric nanoparticles: in vivo evidence of different routes of administration in rodents |
| Q40295370 | Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice |
| Q26850868 | Enabling nanomaterial, nanofabrication and cellular technologies for nanoneuromedicines |
| Q36307467 | Nano-enabled delivery of diverse payloads across complex biological barriers |
| Q38038895 | Nanobiotechnology-based strategies for crossing the blood-brain barrier |
| Q45897427 | Nanotechnology-based strategies for the diagnosis and treatment of intracranial neoplasms |
| Q39154878 | Novel functionalization strategies of polymeric nanoparticles as carriers for brain medications |
| Q48111341 | PLGA Nanoparticles Loaded Cerebrolysin: Studies on Their Preparation and Investigation of the Effect of Storage and Serum Stability with Reference to Traumatic Brain Injury |
| Q26778701 | Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer |
| Q26751294 | Systemic delivery to central nervous system by engineered PLGA nanoparticles |
Search more.